376 related articles for article (PubMed ID: 27451324)
61. Assessment of ospemifene or lubricants on clinical signs of VVA.
Constantine G; Graham S; Koltun WD; Kingsberg SA
J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
[TBL] [Abstract][Full Text] [Related]
62. Fractional CO
Siliquini GP; Tuninetti V; Bounous VE; Bert F; Biglia N
Climacteric; 2017 Aug; 20(4):379-384. PubMed ID: 28503946
[TBL] [Abstract][Full Text] [Related]
63. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
Pinkerton JV; Kagan R
Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
[TBL] [Abstract][Full Text] [Related]
64. Vaginal CO
Pearson A; Booker A; Tio M; Marx G
Breast Cancer Res Treat; 2019 Nov; 178(1):135-140. PubMed ID: 31377895
[TBL] [Abstract][Full Text] [Related]
65. Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study.
Berreni N; Salerno J; Chevalier T; Alonso S; Mares P
BMC Womens Health; 2021 Aug; 21(1):322. PubMed ID: 34454465
[TBL] [Abstract][Full Text] [Related]
66. Ospemifene in clinical practice for vulvo-vaginal atrophy: results at 3 months of follow-up of use.
Pingarron C; de Lafuente P; Ierullo AM; Poyo Torcal S; Maroto Díaz CJ; Palacios S
Gynecol Endocrinol; 2021 Jun; 37(6):562-566. PubMed ID: 33300371
[TBL] [Abstract][Full Text] [Related]
67. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
Bachmann G; Bobula J; Mirkin S
Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
[TBL] [Abstract][Full Text] [Related]
68. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey.
Simon JA; Kokot-Kierepa M; Goldstein J; Nappi RE
Menopause; 2013 Oct; 20(10):1043-8. PubMed ID: 23571518
[TBL] [Abstract][Full Text] [Related]
69. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
[TBL] [Abstract][Full Text] [Related]
70. Treatment to External Labia and Vaginal Canal With CO2 Laser for Symptoms of Vulvovaginal Atrophy in Postmenopausal Women.
Samuels JB; Garcia MA
Aesthet Surg J; 2019 Jan; 39(1):83-93. PubMed ID: 29726916
[TBL] [Abstract][Full Text] [Related]
71. The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause.
Particco M; Djumaeva S; Nappi RE; Panay N; Palacios S;
Menopause; 2020 Apr; 27(4):423-429. PubMed ID: 32068686
[TBL] [Abstract][Full Text] [Related]
72. Recognizing and treating urogenital atrophy in postmenopausal women.
Goldstein I
J Womens Health (Larchmt); 2010 Mar; 19(3):425-32. PubMed ID: 20156082
[TBL] [Abstract][Full Text] [Related]
73. Vaginal natural oxygenation device (VNOD) for concomitant administration of hyaluronic acid and topical hyperbaric oxygen to treat vulvo-vaginal atrophy: a pilot study.
Condemi L; Di Giuseppe J; Delli Carpini G; Garoia F; Frega A; Ciavattini A
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8480-8486. PubMed ID: 30556890
[TBL] [Abstract][Full Text] [Related]
74. Safety and efficacy of non-ablative CO
Lami A; Alvisi S; Baldassarre M; Zanella S; Amati V; Seracchioli R; Meriggiola MC
Arch Gynecol Obstet; 2024 Apr; 309(4):1575-1583. PubMed ID: 38253692
[TBL] [Abstract][Full Text] [Related]
75. The CLOSER survey: impact of postmenopausal vaginal discomfort on women and male partners in the UK.
Domoney C; Currie H; Panay N; Maamari R; Nappi RE
Menopause Int; 2013 Jun; 19(2):69-76. PubMed ID: 23778561
[TBL] [Abstract][Full Text] [Related]
76. Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Pagano T; De Rosa P; Vallone R; Schettini F; Arpino G; De Placido S; Nazzaro G; Locci M; De Placido G
Menopause; 2016 Oct; 23(10):1108-13. PubMed ID: 27648595
[TBL] [Abstract][Full Text] [Related]
77. Genitourinary syndrome of menopause in five Asian countries: results from the Pan-Asian REVIVE survey.
Chua Y; Limpaphayom KK; Cheng B; Ho CM; Sumapradja K; Altomare C; Huang K
Climacteric; 2017 Aug; 20(4):367-373. PubMed ID: 28453308
[TBL] [Abstract][Full Text] [Related]
78. Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders.
Erekson EA; Li FY; Martin DK; Fried TR
Menopause; 2016 Apr; 23(4):368-75. PubMed ID: 26645820
[TBL] [Abstract][Full Text] [Related]
79. The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA study.
Palma F; Xholli A; Cagnacci A;
Maturitas; 2018 Feb; 108():18-23. PubMed ID: 29290210
[TBL] [Abstract][Full Text] [Related]
80. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
